4D Molecular Therapeutics (FDMT) Change in Receivables (2020 - 2022)
4D Molecular Therapeutics (FDMT) posted quarterly Change in Receivables of -$47000.0 for Q1 2022, up 90.98% year-over-year from -$24610.1 in Q1 2021, and up 93.68% quarter-over-quarter from -$744000.0 in Q4 2021.
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Change in Receivables (2020 - 2022) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Change in Receivables for 3 consecutive years, with -$47000.0 the latest figure, recorded in Q1 2022.
- In Q1 2022, Change in Receivables rose 90.98% year-over-year to -$47000.0; the TTM figure through Dec 2022 stood at -$47000.0 (up 96.73% YoY), while the FY2022 annual figure was -$47000.0, up 96.73% from the prior year.
- Change in Receivables advanced to -$47000.0 in Q1 2022 per FDMT's latest filing, from -$744000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $590000.0 in Q4 2020 and bottomed at -$744000.0 in Q4 2021.
- Historically, Change in Receivables has averaged -$108666.7 across 3 years, with a median of -$99000.0 in 2020.
- On a YoY basis, Change in Receivables climbed as much as 267.55% in 2021 and fell as far as 426.26% in 2021.
- 4D Molecular Therapeutics' Change in Receivables stood at $590000.0 in 2020, then plunged by 226.1% to -$744000.0 in 2021, then surged by 93.68% to -$47000.0 in 2022.
- Business Quant data shows FDMT's Change in Receivables at -$47000.0 in Q1 2022, -$744000.0 in Q4 2021, and -$427000.0 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | -47,000.00 |
| Dec 31, 2021 | -744,000.00 |
| Sep 30, 2021 | -427,000.00 |
| Jun 30, 2021 | 253,000.00 |
| Mar 31, 2021 | -521,000.00 |
| Dec 31, 2020 | 590,000.00 |
| Sep 30, 2020 | 168,000.00 |
| Jun 30, 2020 | -151,000.00 |
| Mar 31, 2020 | -99,000.00 |